tiprankstipranks
Trending News
More News >
Ayurcann Holdings Corp. (TSE:AYUR)
:AYUR
Advertisement

Ayurcann Holdings Corp. (AYUR) AI Stock Analysis

Compare
1 Followers

Top Page

TSE:AYUR

Ayurcann Holdings Corp.

(AYUR)

Select Model
Select Model
Select Model
Neutral 51 (OpenAI - 4o)
Rating:51Neutral
Price Target:
C$0.00
▼(-100.00% Downside)
Ayurcann Holdings Corp. shows significant growth potential, primarily driven by recent record revenue and market share expansion. However, substantial financial and operational challenges, including consistent net losses and negative cash flows, weigh heavily on the overall score. Technical analysis provides some support, but valuation remains unattractive due to ongoing losses. The company's strategic initiatives and market positioning are positive, yet addressing financial health is crucial for sustainable growth.

Ayurcann Holdings Corp. (AYUR) vs. iShares MSCI Canada ETF (EWC)

Ayurcann Holdings Corp. Business Overview & Revenue Model

Company DescriptionAyurcann Holdings Corp. (AYUR) is a Canadian company primarily engaged in the cannabis industry, focusing on the extraction and production of various cannabis-derived products. The company operates in sectors including pharmaceutical, wellness, and recreational cannabis markets, offering a range of products such as cannabis oils, distillates, and other derivative products that serve both medical and adult-use consumers.
How the Company Makes MoneyAyurcann Holdings Corp. generates revenue through the extraction and processing of cannabis into oils and distillates, which are then sold to licensed producers and manufacturers in the cannabis industry. The company operates a business-to-business model, providing high-quality extracts and white-label manufacturing services. Its revenue streams include contracts with cannabis producers for extraction services, as well as sales of its own branded products. Significant partnerships with other cannabis companies enhance its market reach and capacity, contributing to its earnings.

Ayurcann Holdings Corp. Financial Statement Overview

Summary
Despite strong revenue growth, Ayurcann Holdings Corp. faces significant financial challenges, including persistent net losses, negative cash flows, and increased financial leverage, signaling operational inefficiencies and potential financial instability.
Income Statement
45
Neutral
Ayurcann Holdings Corp. has shown significant revenue growth, from $611,829 in 2020 to $28,674,900 in the TTM (Trailing-Twelve-Months) 2024, indicating strong top-line expansion. However, the company has consistently reported negative net income, with a net profit margin of -12.18% in TTM 2024. The negative EBIT and EBITDA margins highlight ongoing operational inefficiencies and profitability challenges.
Balance Sheet
40
Negative
The debt-to-equity ratio has worsened as the equity base has significantly shrunk to $166,399 in TTM 2024 from $4,749,223 in 2021. This highlights a concerning increase in financial leverage. Additionally, the equity ratio has declined, indicating a higher reliance on debt financing, which could pose risks if the company's operational losses persist.
Cash Flow
38
Negative
The cash flow situation remains challenging, with a negative operating cash flow of -$1,029,359 in TTM 2024, indicating that the company is not generating sufficient cash from its operations. The free cash flow to net income ratio is negative, and free cash flow has continued to deteriorate, reflecting ongoing cash burn and potential liquidity concerns.
BreakdownTTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income Statement
Total Revenue28.67M25.16M12.49M9.39M7.63M611.83K
Gross Profit10.49M8.46M3.68M2.22M4.63M371.40K
EBITDA-1.51M-2.01M-4.50M-3.01M653.98K-245.00K
Net Income-3.49M-3.97M-5.31M-3.09M-278.00K-237.00K
Balance Sheet
Total Assets16.17M14.85M12.73M7.28M6.68M1.13M
Cash, Cash Equivalents and Short-Term Investments1.33M639.09K971.96K1.35M725.02K1.12M
Total Debt1.03M894.64K180.90K356.08K475.04K484.31K
Total Liabilities16.01M14.32M10.04M2.39M1.93M18.27K
Stockholders Equity166.40K534.88K2.69M4.89M4.75M1.11M
Cash Flow
Free Cash Flow-1.05M-534.84K-568.67K-312.71K-707.55K-637.10K
Operating Cash Flow-1.03M-96.89K-271.30K-50.09K-198.56K-235.95K
Investing Cash Flow-25.19K-437.94K-297.38K-262.62K363.25K-401.15K
Financing Cash Flow-528.53K-48.03K185.82K942.51K537.89K245.24K

Ayurcann Holdings Corp. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.04
Price Trends
50DMA
0.03
Positive
100DMA
0.03
Positive
200DMA
0.03
Positive
Market Momentum
MACD
<0.01
Negative
RSI
83.81
Negative
STOCH
55.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AYUR, the sentiment is Positive. The current price of 0.04 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and above the 200-day MA of 0.03, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 83.81 is Negative, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:AYUR.

Ayurcann Holdings Corp. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
C$6.25M-40.824.04%80.24%
51
Neutral
C$7.79M-271.33%27.80%31.16%
49
Neutral
C$420.72K-0.31-100.00%43.66%
39
Underperform
C$4.58M-0.18-34.09%71.95%
38
Underperform
C$10.63M-1.83-100.00%-8.70%
31
Underperform
C$2.42M-0.64563.34%-68.82%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:AYUR
Ayurcann Holdings Corp.
0.04
0.00
0.00%
TSE:DHB
Delivra Health Brands
0.22
-0.03
-12.00%
TSE:FFNT
4Front Ventures
0.01
-0.06
-85.71%
TSE:LOBE
Lobe Sciences
0.06
0.04
175.00%
TSE:AION
Aion Therapeutic Inc
0.01
-0.01
-50.00%
TSE:XBRA
Xebra Brands Ltd.
0.01
-0.03
-75.00%

Ayurcann Holdings Corp. Corporate Events

Business Operations and StrategyFinancial Disclosures
Ayurcann Holdings Corp. Reports Record Q3 2025 Growth and Expands Market Presence
Positive
May 16, 2025

Ayurcann Holdings Corp. reported record-breaking financial results for Q3 2025, with a gross revenue of $14,179,974, marking a 22% year-over-year increase. The company has achieved significant market share, being a top 3 vape producer in Ontario and holding a 5% national market share. With a focus on operational efficiency and a growing national footprint, Ayurcann is well-positioned for sustainable growth, despite industry challenges. The company is actively expanding its product categories and geographic reach to drive future revenue growth.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 01, 2025